IN2015DN04089A - - Google Patents

Info

Publication number
IN2015DN04089A
IN2015DN04089A IN4089DEN2015A IN2015DN04089A IN 2015DN04089 A IN2015DN04089 A IN 2015DN04089A IN 4089DEN2015 A IN4089DEN2015 A IN 4089DEN2015A IN 2015DN04089 A IN2015DN04089 A IN 2015DN04089A
Authority
IN
India
Prior art keywords
enantiomers
signifies
alkyl alkylaryl
alkylheteroaryl
proviso
Prior art date
Application number
Other languages
English (en)
Inventor
Da Silva Patrício Manuel Vieira Araújo Soares
Maria João Macedo Da Silva Bonifácio
Original Assignee
BIAL PORTELA & Cª S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIAL PORTELA & Cª S A filed Critical BIAL PORTELA & Cª S A
Publication of IN2015DN04089A publication Critical patent/IN2015DN04089A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN4089DEN2015 2012-11-14 2013-11-14 IN2015DN04089A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261726119P 2012-11-14 2012-11-14
PCT/PT2013/000065 WO2014077715A1 (en) 2012-11-14 2013-11-14 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury

Publications (1)

Publication Number Publication Date
IN2015DN04089A true IN2015DN04089A (enExample) 2015-10-09

Family

ID=49759506

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4089DEN2015 IN2015DN04089A (enExample) 2012-11-14 2013-11-14

Country Status (23)

Country Link
US (3) US9604970B2 (enExample)
EP (1) EP2919780B1 (enExample)
JP (1) JP6373275B2 (enExample)
KR (1) KR102259938B1 (enExample)
CN (1) CN105025895B (enExample)
AU (1) AU2013345494B2 (enExample)
BR (1) BR112015010969B1 (enExample)
CA (1) CA2890920C (enExample)
CY (1) CY1120953T1 (enExample)
DK (1) DK2919780T3 (enExample)
ES (1) ES2693025T3 (enExample)
HR (1) HRP20181651T1 (enExample)
IN (1) IN2015DN04089A (enExample)
LT (1) LT2919780T (enExample)
MX (1) MX355422B (enExample)
PL (1) PL2919780T3 (enExample)
PT (1) PT2919780T (enExample)
RS (1) RS57874B1 (enExample)
RU (1) RU2718055C2 (enExample)
SI (1) SI2919780T1 (enExample)
SM (1) SMT201800560T1 (enExample)
TR (1) TR201815850T4 (enExample)
WO (1) WO2014077715A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN04089A (enExample) 2012-11-14 2015-10-09 BIAL PORTELA & Cª S A
GB201810395D0 (en) * 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
CN118598820B (zh) * 2024-02-06 2025-07-08 石家庄四药有限公司 一种二苯基三嗪类化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623107B2 (ja) * 1990-11-16 1994-03-30 帝人株式会社 プロスタサイクリン類を有効成分とする薬学的組成物
HUT76295A (en) * 1994-04-26 1997-07-28 Syntex Inc Imidazolyl- and triazolyl-thion derivatives, pharmaceutical compositions containing them and process for producing them
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
US20040102361A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
GB0600709D0 (en) * 2006-01-13 2006-02-22 Portela & Ca Sa Drug combinations
GB0610804D0 (en) * 2006-05-31 2006-07-12 Portela & Ca Sa New crystal forms
GB0700635D0 (en) * 2007-01-12 2007-02-21 Portela & Ca Sa Therapy
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
EP2231648A1 (en) * 2007-12-05 2010-09-29 BIAL - Portela & Ca., S.A. New salts and crystal forms
JP2011508775A (ja) * 2008-01-03 2011-03-17 ビオマリン プハルマセウトイカル インコーポレイテッド Ｂｈ４応答性状態を治療するためのプテリン類似体
AR070841A1 (es) * 2008-03-13 2010-05-05 Bial Portela & Ca Sa Proceso de hidrogenacion catalitica asimetrica
AR071632A1 (es) * 2008-05-06 2010-06-30 Bial Portela & Ca Sa Proceso catalitico para hidrogenacion asimetrica en la sintesis de inhibidores de la dopamina-beta-hidroxilasa"
DE102008054205A1 (de) * 2008-10-31 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie
RU2604734C2 (ru) * 2010-12-22 2016-12-10 БИАЛ-ПОРТЕЛА энд КА., С.А. Кристаллическая форма и способ ее очистки
IN2015DN04089A (enExample) 2012-11-14 2015-10-09 BIAL PORTELA & Cª S A

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera

Also Published As

Publication number Publication date
EP2919780B1 (en) 2018-08-01
MX2015005910A (es) 2015-08-10
CY1120953T1 (el) 2020-05-29
BR112015010969B1 (pt) 2020-05-26
AU2013345494B2 (en) 2018-03-22
HRP20181651T1 (hr) 2018-12-14
US10308640B2 (en) 2019-06-04
MX355422B (es) 2018-04-18
CN105025895A (zh) 2015-11-04
US20190241545A1 (en) 2019-08-08
RU2015120164A (ru) 2017-01-10
CN105025895B (zh) 2019-02-26
SI2919780T1 (sl) 2018-12-31
DK2919780T3 (en) 2018-11-26
EP2919780A1 (en) 2015-09-23
TR201815850T4 (tr) 2018-11-21
PT2919780T (pt) 2018-11-13
RU2718055C2 (ru) 2020-03-30
JP6373275B2 (ja) 2018-08-15
WO2014077715A1 (en) 2014-05-22
CA2890920C (en) 2020-12-15
KR20150084022A (ko) 2015-07-21
JP2016504286A (ja) 2016-02-12
ES2693025T3 (es) 2018-12-07
SMT201800560T1 (it) 2019-01-11
BR112015010969A2 (pt) 2017-08-22
HK1215393A1 (en) 2016-08-26
RS57874B1 (sr) 2018-12-31
AU2013345494A1 (en) 2015-05-14
KR102259938B1 (ko) 2021-06-03
US20170369477A1 (en) 2017-12-28
US20150299172A1 (en) 2015-10-22
LT2919780T (lt) 2018-11-12
CA2890920A1 (en) 2014-05-22
PL2919780T3 (pl) 2019-01-31
US9604970B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
ES2531324T3 (es) Intermedio para producir un derivado de gamma-aminoácido bicíclico
MX375718B (es) [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
MX2007004699A (es) Derivados de indol y bencimidazol.
GB0708818D0 (en) Compounds
UA102310C2 (ru) Гетероциклические сульфонамиды, их применение и фармацевтические композиции
NZ596615A (en) Substituted isoquinoline derivative
UA97821C2 (en) Cyclized derivatives as eg-5 inhibitors
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
TW200716084A (en) Methods for treating sleep-wake disorders
MY170262A (en) Dicarboxylic acid compound
IN2015DN04089A (enExample)
AR035521A1 (es) Derivados de 3-indolina y composicion farmaceutica que los comprende
UA96947C2 (ru) Производные циннамоил-пиперазина и их применение как антагонистов par-1
ATE404536T1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
PH12018502012B1 (en) Griseofulvin compound
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
NZ706418A (en) Azaquinazoline carboxamide derivatives
CR20130476A (es) Derivados de pirazolidin-3-ona
TN2015000490A1 (fr) Dérivés d'imidazo-triazine servant d' inhibiteurs de pde10
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
MX2009010225A (es) Nuevos compuestos 707 y sus usos.
MY160253A (en) Prophylactic or ameliorating agent for pigmentation
MX2010008196A (es) Derivados de acido 4-dimetilaminobutirico.
EA201491878A1 (ru) Замещенные ксантиновые производные
GB2483195A (en) Novel uses